1. Home
  2. LYRA

LYRA

Lyra Therapeutics Inc.

Logo Lyra Therapeutics Inc.

Health Care

Medical/Dental Instruments

Nasdaq

as 04-16-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Founded: 2005 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 315.4M IPO Year: 2020
Target Price: $12.67 AVG Volume (30 days): 338.5K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.26 EPS Growth: N/A
52 Week Low/High: $1.93 - $6.79 Next Earning Date: 05-10-2024
Revenue: $1,558,000 Revenue Growth: 14.31%
Revenue Growth (this year): -9.69% Revenue Growth (next year): -43.35%

Share on Social Networks: